Retatrutide qué es: learn what this investigational triple-agonist drug is, how it works in trials, dosing, side effects, and why it is not FDA-approved.
Retatrutide is an investigational injectable drug from Eli Lilly that activates three hormone receptors at once: GLP-1, GIP, and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not FDA-approved for human use in the United States. The Spanish phrase "retatrutide qué es" translates to "what is retatrutide," and the short answer is that it is a next-generation weight-loss candidate still working through phase 3 trials.
Retatrutide: Qué Es in Plain English
People searching retatrutide en español are looking for the same basic facts as everyone else: what the drug is, how it works, and whether they can get it. Retatrutide is a synthetic peptide given as a once-weekly subcutaneous injection.
- Drug class: triple agonist (GLP-1, GIP, and glucagon receptors)
- Developer: Eli Lilly and Company; internal code LY3437943
- Route: subcutaneous injection, once weekly
- Main uses under study: obesity and type 2 diabetes
- Regulatory status: investigational — no approval from the FDA or any other agency as of this writing
How Retatrutide Works in the Body
Retatrutide is not a single-pathway drug. Each of its three receptor targets does something different, and the combination is what separates it from older options.
- GLP-1: slows stomach emptying, blunts appetite, and improves blood sugar control.
- GIP: influences insulin release and how the body handles fat.
- Glucagon: raises energy expenditure, which may help the body burn more calories at rest.
A frequent search question — is retatrutide a glp-3 — comes from that three-receptor design, but there is no such thing as a GLP-3 receptor class. The accurate label is "triple agonist," and some researchers use "GLP-3" informally as shorthand.
Retatrutide for obesity is the indication that draws the most attention, and it is also the one with the largest ongoing phase 3 program.
What the Clinical Trials Have Shown So Far
The most-cited human data come from a phase 2 trial published in the New England Journal of Medicine in 2023. It followed 338 adults with obesity but without diabetes for 48 weeks of treatment.
| Weekly dose | Average weight loss at 48 weeks | Notes |
|---|---|---|
| Placebo | About 2% | Diet and exercise counseling only |
| 1 mg | About 9% | Lowest active dose |
| 4 mg | About 17% | Mid-range dose |
| 8 mg | About 23% | Participants were still losing weight at week 48 |
| 12 mg | About 24% | Highest dose tested |
A separate phase 2 study in people with type 2 diabetes reported large A1c reductions, which is why the drug is being studied for both conditions. Phase 3 results are not yet public, and final numbers often shift once thousands of participants are enrolled.
Dosing and How Long It Takes to Work
Researchers have tested weekly doses between 1 mg and 12 mg, with gradual step-ups to limit stomach-related side effects. Weight loss builds over months rather than days.
People searching how long does retatrutide take to work should expect early appetite changes within the first few weeks and measurable fat loss over three to six months. In the phase 2 trial, participants were still losing weight at the 48-week mark.
Because retatrutide is not approved, there is no standard public dosing schedule. Injection outside a supervised clinical trial means using a product no regulator has reviewed.
Cagrilintide vs Retatrutide vs Tirzepatide
Side-by-side searches like cagrilintide vs retatrutide vs tirzepatide come up often because all three aim at weight loss through different hormone pathways. They are not interchangeable.
| Drug | Mechanism | Developer | Reported weight loss | Status |
|---|---|---|---|---|
| Tirzepatide (Zepbound) | GIP + GLP-1 dual agonist | Eli Lilly | About 21% at 72 weeks (15 mg) | FDA-approved |
| Retatrutide | GLP-1 + GIP + glucagon triple agonist | Eli Lilly | About 24% at 48 weeks (12 mg) | Investigational |
| Cagrilintide | Amylin analog, often paired with semaglutide as CagriSema | Novo Nordisk | About 23% at 68 weeks (CagriSema) | Investigational |
Researchers comparing aod 9604 and retatrutide are looking at two very different mechanisms. AOD 9604 is a fragment of human growth hormone studied for fat metabolism, while retatrutide works through gut and pancreatic hormone receptors.
Brand Name, Availability, and Legal Status
Eli Lilly has not announced a retatrutide brand name, and no country has approved the drug for sale. That means there is no legal prescription version, no pharmacy supply, and no standard price.
Peptides sold online as "retatrutide" are unregulated research chemicals. Their identity, purity, and sterility are not guaranteed, and independent testing has repeatedly found vials that do not match their labels.
Side Effects and Safety
In trials, the most common complaints were gastrointestinal and generally mild to moderate.
- Nausea, vomiting, and diarrhea
- Constipation and reduced appetite
- Injection-site reactions
- Higher resting heart rate
- Skin tingling or sensitivity (dysesthesia) at the 12 mg dose
Retatrutide is not a proven cure for obesity, and long-term safety data do not exist yet. Anyone considering a GLP-1-type medication should talk with a healthcare professional about approved options first.
Frequently Asked Questions
Is retatrutide FDA-approved?
No. Retatrutide is an investigational drug and has not been approved by the FDA or any other regulatory agency. It is only legally available to participants enrolled in clinical trials, so any vial sold online is an unregulated research chemical.
How does retatrutide compare to tirzepatide and semaglutide?
Tirzepatide (Zepbound) is an FDA-approved dual GIP/GLP-1 agonist linked to roughly 21% weight loss at 72 weeks, and semaglutide (Wegovy) is an approved GLP-1 agonist linked to about 15%. Retatrutide produced roughly 24% weight loss at 48 weeks in a phase 2 trial, but these are cross-trial comparisons rather than head-to-head studies, and retatrutide is not approved.
What are the most common retatrutide side effects?
The most frequently reported side effects in trials were nausea, diarrhea, vomiting, and constipation, along with injection-site reactions and a modest rise in resting heart rate. Some participants at the highest dose reported skin tingling or unusual skin sensitivity, and most effects were mild to moderate.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.